UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for migraine in the United Kingdom. Explore treatment pathways including CGRP inhibitors, Botox, and novel acute and preventive therapies.
Migraine affects ~10 million people in the UK (~15% of the population). It is much more than a headache - causing intense head pain, nausea, sensitivity to light and sound, and sometimes visual disturbances (aura). Chronic migraine (≥15 days/month) affects ~2% of the population and is one of the most disabling conditions globally. It is the 6th highest cause of years lost to disability worldwide.
CGRP (calcitonin gene-related peptide) inhibitors have transformed migraine treatment. Preventive CGRP antibodies: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality) - monthly or quarterly injections. NICE recommends these for chronic or episodic migraine after 3+ preventive medication failures. Acute CGRP antagonists (gepants): rimegepant (Piqray), atogepant - oral tablets that stop migraine attacks without causing medication overuse headache.
Acute treatments: triptans (sumatriptan, rizatriptan) for attacks, combined with NSAIDs. Preventive treatments: beta-blockers (propranolol), antidepressants (amitriptyline), anticonvulsants (topiramate), or CGRP antibodies. For chronic migraine: Botox (onabotulinumtoxinA, 31 injections every 12 weeks) - NICE approved. Newer options: neuromodulation devices (Cefaly, gammaCore) and CGRP gepants.
Active UK migraine trials include: next-generation CGRP inhibitors with longer dosing intervals, dual-action gepants, novel preventive targets (PACAP, oxytocin), precision medicine approaches, neuromodulation devices, and digital therapies. The National Migraine Centre and NHS headache clinics are key trial sites.
Free AI-powered matching - no signup required
Search chronic migraine Trials →